Janus激酶抑制剂在皮肤科的应用:系统综述
JAK抑制剂在银屑病中研究广泛,疗效与依tn接受者(etanercept)相当;斑秃也观察到良好结果,白癜风、皮炎、移植物抗宿主病、皮肤T细胞淋巴瘤和红斑狼疮有初步积极结果。最常见不良事件为感染,多为鼻咽炎和上呼吸道感染。
要点
- JAK抑制剂在银屑病中疗效与依那西普(etanercept)相当。
- 斑秃也观察到良好结果,多个其他皮肤病有初步积极结果。
- 最常见不良事件为感染,多为鼻咽炎和上呼吸道感染。
核心结论
- JAK抑制剂对多种皮肤病有前景,但皮肤科适应症的正确剂量与安全性特征仍存在空白,需更多试验。
主要发现
- JAK抑制剂在银屑病中研究广泛,疗效与依那西普(etanercept)相当。
- 斑秃也观察到良好结果。
- 白癜风、皮炎、移植物抗宿主病、皮肤T细胞淋巴瘤和红斑狼疮报告了初步积极结果。
- 最常见不良事件为感染,多为鼻咽炎和上呼吸道感染。
临床怎么用
- JAK抑制剂可用于银屑病和斑秃等皮肤病,但需关注感染风险并个体化评估。
局限性
- 无法对结果进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Janus kinase (JAK) inhibitors are emerging as a promising new treatment modality for many inflammatory conditions. OBJECTIVE: Our aim was to systematically review the available data on the use of JAK inhibitors in cutaneous diseases. METHODS: This is a systematic review of PubMed and ClinicalTrials.gov. RESULTS: One hundred thirty-four articles matched our search terms, of which 78 were original articles and 12 reports on adverse events. Eighteen clinical trials were found. JAK inhibitors have been extensively studied for psoriasis, showing beneficial results that were comparable to the effects achieved by etanercept. Favorable results were also observed for alopecia areata. Promising preliminary results were reported for vitiligo, dermatitis, graft versus host disease, cutaneous T cell lymphoma, and lupus erythematosus. The most common adverse events reported were infections, mostly nasopharyngitis and upper respiratory tract infections. LIMITATIONS: It was not possible to perform a meta-analysis of the results. CONCLUSIONS: This systematic review shows that while JAK inhibitors hold promise for many skin disorders, there are still gaps regarding the correct dosing and safety profile of these medications for dermatologic indications. Additional trials are necessary to address these gaps.
引用
- Shreberk-Hassidim R, Ramot Y, Zlotogorski A, et al. Janus kinase inhibitors in dermatology: A systematic review. J Am Acad Dermatol. 2017. PMID: 28169015. doi:10.1016/j.jaad.2016.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。